Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Brandi

Showing results (31-40 of 246) with videos related to

Pageof 25
Sort By:
Expert Opinion on Investigational Drugs|October 15, 2020
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectivesAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
ESMO Open|September 30, 2020
The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora's box?Angela Dalia Ricci, Alessandro Rizzo, Giovanni Brandi
Hepatobiliary & Pancreatic Diseases International : HBPD INT|December 18, 2020
Combination therapy of dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutated biliary tract cancerAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
The Lancet. Oncology|January 1, 2022
Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancerAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Immunotherapy|April 6, 2021
Atezolizumab in advanced hepatocellular carcinoma: good things come to those who waitAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
The Oncologist|February 4, 2021
In Regard to "A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)"Angela Dalia Ricci, Alessandro Rizzo, Giovanni Brandi
Translational Gastroenterology and Hepatology|February 1, 2017
Cholangiocarcinoma: from risk to prevention?Giovanni Brandi, Stefania De Lorenzo, Francesco Tovoli
Liver Cancer|May 31, 2022
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
The Oncologist|August 22, 2022
Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular CarcinomaAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Cancer Treatment and Research Communications|April 2, 2021
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Pageof 25

Showing results (31-40 of 246) with videos related to

Sort By:
Pageof 25
Expert Opinion on Investigational Drugs|October 15, 2020
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectivesAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
ESMO Open|September 30, 2020
The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora's box?Angela Dalia Ricci, Alessandro Rizzo, Giovanni Brandi
Hepatobiliary & Pancreatic Diseases International : HBPD INT|December 18, 2020
Combination therapy of dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutated biliary tract cancerAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
The Lancet. Oncology|January 1, 2022
Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancerAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Immunotherapy|April 6, 2021
Atezolizumab in advanced hepatocellular carcinoma: good things come to those who waitAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
The Oncologist|February 4, 2021
In Regard to "A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)"Angela Dalia Ricci, Alessandro Rizzo, Giovanni Brandi
Translational Gastroenterology and Hepatology|February 1, 2017
Cholangiocarcinoma: from risk to prevention?Giovanni Brandi, Stefania De Lorenzo, Francesco Tovoli
Liver Cancer|May 31, 2022
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
The Oncologist|August 22, 2022
Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular CarcinomaAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Cancer Treatment and Research Communications|April 2, 2021
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Pageof 25